Toronto, Canada (PRWEB) July 25, 2013
Diabetes is the seventh leading cause of death in the U.S. and affects over 350 million people worldwide, according to the World Health Organization. It is estimated that one in six men will be diagnosed with prostate cancer in their lifetime — the second most common cancer in the world.
Not surprisingly, drug developers are currently working on over 500 clinical trials for hormone or steroid-driven diseases, such as prostate cancer, diabetes and other metabolic diseases.
Detection of very low levels of hormones and related molecules are an important facet of monitoring investigational agents that target these diseases and allows for a more informed understanding of drug response and optimization of dose, regimen and treatment during clinical development.
In this webinar, an overview of clinically relevant assays for ultrasensitive endocrine clinical trial testing services will be discussed by LabCorp scientists, Dr. Walt Chandler, Head of R&D for Endocrine Sciences, and Dr. Patrice Hugo, Senior Director of Global Scientific Affairs.
Ongoing and future LabCorp projects, such as proprietary assays for diabetes, bone metabolism, thyroid and adrenal function, development and reproduction using age-related reference ranges will also be highlighted in this presentation.
To learn more about the event, visit http://www.xtalks.com/advancements-in-endocrine-testing.ashx.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issu
Copyright©2012 Vocus, Inc.
All rights reserved